- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Phase-3 trial of COVAXIN to begin in Lucknow, Gorakhpur from October
![Phase-3 trial of COVAXIN to begin in Lucknow, Gorakhpur from October Phase-3 trial of COVAXIN to begin in Lucknow, Gorakhpur from October](https://medicaldialogues.in/h-upload/2020/06/30/750x450_131039-coronavirus-vaccine.webp)
Lucknow: The Uttar Pradesh government on Thursday announced that phase-3 trial of the coronavirus vaccine 'COVAXIN' will start in Lucknow and Gorakhpur from October.
"The phase-3 trial of COVAXIN being developed by Bharat Biotech will start in Lucknow and Gorakhpur from October," said Uttar Pradesh Principal Health Secretary Amit Mohan Prasad here in a press conference.
The Indian Council for Medical Research (ICMR) is collaborating with Bharat Biotech for the development of the COVAXIN.
Meanwhile, Congress leader Deepak Singh on Thursday wrote a letter to Chief Minister Yogi Adityanath and requested to increase testing for Covid-19 in Uttar Pradesh.
According to the Union Health Ministry as of Thursday, there are 61,698 active cases in the state with 3,02,689 recovered people and 5,299 deaths.
Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751
Next Story